ArticleAnnals of surgical oncology2026

Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response.

Aleigha Lawless et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.